HUB Organoids is the sole proprietor of patient-derived organoid technology, offering essential contract research services using its living organoid biobank and licensing opportunities.

Known as the global leader of adult stem cell-derived organoids, HUB Organoids can help you at every step of the preclinical process – from target validation and lead selection to preclinical patient stratification and clinical trial patient selection.

Our commitment to disruptive innovation extends to the development of novel organoid-based model systems and assays, allowing us to tailor solutions that align with our client’s unique research hypothesis.

We provide services across diverse therapeutic areas, including oncology, inflammation, genetic disease, toxicology, and infectious disease.

Visit www.huborganoids.nl to learn more